Review Scottish

Total Page:16

File Type:pdf, Size:1020Kb

Review Scottish INNOVATION TECHNOLOGY HEALTHCARE PHARMACY Scottish Review BIOSIMILAR MEDICINES WHAT YOU NEED TO KNOW CPD AN UPDATE WORD ON THE STREET HOMELESSNESS AND PHARMACISTS DOLLY THE SHEEP A 20-YEAR LEGACY SUMMER SPECIAL 2017 HEALTH HAZARDS IN THE SPOTLIGHT ISSUE 116 - 2017 VISIT US AT WWW.SCOTHEALTHCARE.COM 5688 QIPP advertorial in Northern Ireland Healthcare Review (NIH) v1.qxp_QIPP Zeroderma advertorial 18/01/2017 13:43 Page 1 wIdER CHoICE, GREATER SAvINGS FRom THE ZERodERmA RANGE How much could you save on emollient prescribing? The Zeroderma emollient range offers a choice of four creams, one ointment, Survey shows benefits of ® 19% Zerodouble Emollient Gel cost saving one gel and two bath additives - per pack providing complete emollient therapy Results from a recent survey with over 300 members of ® for moisturising, washing and bathing. the Psoriasis Association using Zerodouble emollient Gel showed that 97% liked the feel of Zerodouble Gel, 91% All Zeroderma products are gentle on said it was as good as or better than their current emollient the skin and do not contain the harmful and 84% wanted to continue using Zerodouble Gel. irritant sodium lauryl sulfate (SlS). Zeroderm® ointment – convenient 37% Zeroderma products are similar in formulation cost saving to around 50% of emollients currently 3-in-1 emollient therapy per pack prescribed by CCGs and offer cost savings SLS-free Zeroderm® Ointment provides a rich of up to 37%, with no compromise on 3-in-1 emollient for the management of eczema and dry skin conditions. Zeroderm Ointment can patient care. Around 75% of formularies and be used as a skin cleanser, a bath additive and as a leave-on moisturiser. prescribing guidelines already include at least one Zeroderma product. The ZeroAQS® Cream – An SlS-free 24% cost saving Zeroderma emollient range is available on alternative to Aqueous Cream per pack prescription and listed on NHS contract. ZeroAQS® emollient cream is a cost effective A CCG who recently started using the 2-in-1 moisturiser and soap substitute which does Zeroderma range commented: not contain sodium lauryl sulfate (SLS), fragrance or colour. The Medicines and Healthcare products Regulatory Agency (MHRA) ‘Emollient prescribing has been a has directed that SLS-containing Aqueous Cream should carry a safety warning useful area to address as part of stating that: ‘aqueous cream may cause skin irritation due to its sodium lauryl sulfate (SLS) content,’ if used as a leave-on emollient. QIPP. The focus has been on optimising patient care by offering emollient products that patients are happy to use. QIPP By changing from proprietary emollient brands Feedback from GPs has been positive to the cost-effective Zeroderma emollient range, and changes have been simple to ToolkIT the NHS could save over £13 million1 p.a. implement. Patient care has not been A QIPP & emollients toolkit developed by Medicines Management compromised and changes to the teams contains everything needed to implement product changes product prescribed have been at practice level. To estimate your potential local savings and find out 6 1 acceptable to most patients.’ more please visit: www.qipp.trderma.co.uk 0 2 h c r Thornton & Ross, Linthwaite, a M , Huddersfield HD7 5QH a t se a 01484 842217 For FREE samples for patient evaluation plea d A www.trderma.co.uk C P email: [email protected] [email protected] . 1 WWW.SCOTHEALTHCARE.COM SPR WELCOME ISSUE 116 - 2017 MEDCOM www.scothealthcare.com www.pharmacy-life.co.uk Sarah Nelson Editor EDITOR [email protected] SARAH NELSON [email protected] NATIONAL ACCOUNTS MANAGER CHRIS FLANNAGAN [email protected] NATIONAL ACCOUNTS MANAGER (SPECIAL FEATURES) HANNA DEVON [email protected] EDITOR'S LETTER ACCOUNTS MANAGER DONNA MARTIN [email protected] Welcome to the latest edition of Scottish EVENTS MANAGER Pharmacy Review! BRIDGET MCCABE [email protected] STUDIO MANAGER Once upon a time, there was nothing The connection between this season DECLAN NUGENT better than catching the first waft of a and education may evidently resurrect [email protected] flickering barbeque – the universal sign some uneasy feelings for me – but that MANAGING DIRECTOR ADRIAN MAGINNIS that summer was in full swing. Now, doesn’t mean that the time of year isn’t [email protected] however, the aroma fills me, not with a a prime time to broach it. With this in IF YOU WISH TO CONTACT US BY feasting fantasy, but an overwhelming mind, we’re delighted to introduce SPR’s TELEPHONE - 02890 999 441 feeling of dread. Why? Well, it’s all new CPD strand, which is kicked off this Whilst every care has been taken in compiling education’s fault, really. issue with an outline of the personal and this magazine to ensure that it is correct at the time of going to press, the publishers You see, my psychic tendencies may professional benefits of the pursuits – as assume no responsibility for any effects from errors or omissions. The opinions of have not yet reached their full potential well as the systematic changes which you contributors are not necessarily those of the publisher. No part of this publication may be (aka my lottery numbers oddly haven’t need to be aware of (beginning on page reproduced, stored in a retrieval system, or transmitted in any form, or by any means, appeared), but when I was younger, 10). mechanical, electronic, photocopying, recording or otherwise without the prior permission of nobody’s weather-prediction skills Elsewhere, check out this year’s Medical Communications 2015 Ltd. All rights reserved. Data Protection - Please note, your managed to eclipse mine – not even summer special (beginning on page 24) mailing details and copies of any articles supplied will be held on a database and may be Michael Fish’s. – covering inhaler technique findings, shared with associated companies. Sometimes your details may be obtained from, or made Without fail, as I approached my need-to-know allergy updates, and more available to, external companies for marketing purposes. If you do not wish your details to be final years in senior school, and later, – and weigh in on our homeless problem, used for this purpose, please write to: Database Manager, Medical Communications 2015 Ltd, university, the sun soared only on those and how you, the pharmacist, can help 142-148 Albertbridge Road, Belfast, BT5 4GS. Subscription: £120 a year days prior to exams when I was confined (page 16). to the indoors for revision. That’s not all – we once again check in As I tried to soak up knowledge, my with the Scottish Medicines Consortium loved ones sat outside dining and soaking (page 13), and delve into the latest in up the sun; and while I desperately pored nutrition (beginning on page 38). over text books, I could hear the clinking of iced cocktails being poured into Happy reading! INNOVATION TECHNOLOGY HEALTHCARE PHARMACY glasses. I was miserable with jealousy. Scottish Of course, it was only when I exited the exam hall for the final time, smugly CREATED FOR PHARMACISTS Review CRAFTED BY YOU thinking of the prospect of pasta salads CHAMPION ROAD RACING CYCLIST ALEX DOWSETT’S and patio furniture that the summer rain INSIDE TRACK ON HAEMOPHILIA showers decided to open up on me. Year after the year, this was the same old story. IN THIS ISSUE... CROSSING THE LINE THE LATEST ADVICE ON NEW MEDICINES MONEY TALKS DO PAST PENSION SCHEMES HAUNT THE INDUSTRY? GREAT EXPECTATIONS CONFRONT THE FUTURE OF SCOTTISH PHARMACY ISSUE ISSUE EPILEPSY MANAGEMENT 114 HOW THE ROLE OF THE PHARMACIST IS 115 - 2017 - 2017 @MEDCOMscot Medical Communications Ltd BEING REVAMPED VISIT US AT WWW.SCOTHEALTHCARE.COM SPR | June 2017 | 1 There’s strength in numbers That’s why more pharmacies than ever before in Scotland are increasing their profits as members of the Cambrian Alliance Group. Why join them? We’re independent & impartial meaning we’re truly focused on your needs. With over 1,200 members and an annual spending power of £0.5 billion we save you money on generics, PIs, OTCs & dressings. And we give you with the professional services & technology you need to grow your business including e-CASS - our price comparison, stock ordering tool that makes you money and saves you time. Contact us today and start making more money. e: [email protected] t: 0845 130 1187 w: cambrianalliance.co.uk 2 | NIHR | April 2017 Medcom Scot mag advert.indd 1 2/22/2017 9:35:31 AM WWW.SCOTHEALTHCARE.COM CONTENTS ISSUE 116 - 2017 4 HEALTH CENTRE RELAUNCHES Cadham Pharmacy has relaunched as the Cadham Pharmacy Health Centre 7 NEW TO THE GAME What challenges and opportunities are biosimilar medicines bringing to the market? 9 HELLO, DOLLY Credit: The Roslin Institute » p.9 Reflect on Dolly the sheep’s scientific legacy, 20 years on 10 AN EDUCATION Stay sussed on the changing face of CPD in Scotland 14 2017 SCOTTISH PHARMACY CONFERENCE Partake in conversation and debate the motion of, ‘Doctors Diagnose, Pharmacists Prescribe’ » p.32 » p.16 16 WORD ON THE STREET There’s strength in numbers How the sector is helping to reshape the health of the homeless That’s why more pharmacies than ever before in Scotland are increasing 18 ADHD: THE PHARMACIST’S their profits as members of the Cambrian Alliance Group. CHALLENGE Why join them? A new perspective is curbing misdiagnoses of the condition We’re independent & impartial meaning we’re truly focused on your needs. 24 UNDER THE SUN With over 1,200 members and an annual spending power of £0.5 billion » p.7 The latest on the season’s health hazards – from we save you money on generics, PIs, OTCs & dressings.
Recommended publications
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • © 2008 Canadian Medical Association Or Its Licensors
    Early release, published at www.cmaj.ca on April 2, 2012. Subject to revision. March 28, 2012 After not eating for up to 11 days and working out four hours daily, Damian Mangat, then 16 years old, was still dissatisfied with her weight when she came across a novel proposition. While part of an outpatient program at a hospital in Toronto, she met a slender girl who disclosed her technique for keeping thin: drink alcohol while consuming no food. Mangat decided to give it a try. “I thought ‘perfect, I already love to drink when I can get it, and now I won’t have to worry about the dizziness because now when I need energy I can just take a shot of something,” she says. “It seemed to work. It seemed to be the magic answer for me.” Such a coupling of an eating disorder with alcohol abuse has been coined “drunkorexia.” Mangat, now 40 and a mature student at a university in Toronto, says the practice is common among college-age women and she often hears talk of foregoing food to save calories for alcohol. “The thinking is first of all, I’ll save the calories,” she says. “Secondly, I’ll get drunk on less and I’ll look good in what I’m wearing, and then later if I do end up eating, I can always throw it up because the booze makes it easy to throw it up.” Drunkorexia is not recognized in any clinical inventory but shares pop- psychology status with a number of other troublesome behaviours such as orthorexia (an extreme preoccupation with eating foods perceived to be healthy and avoiding foods that are not), manorexia (the male version of anorexia nervosa) and bridorexia (when a bride- to-be fasts to ensure she can fit into a certain size dress).
    [Show full text]
  • Alcohol Responsibly and Ending Tobacco Use, Plus Caffeine - Dr
    MHE-110 – Chapter Nine – Drinking Alcohol Responsibly and Ending Tobacco Use, plus Caffeine - Dr. Dave Shrock Chapter Nine Alcohol - an overview Alcohol and ending Tobacco Use 13th pp. 239-240; 12th pp. 232-223 • alcohol is the most widely used drug in the United (including caffeine) States • 86% of Americans consume alcohol 13th edition, pp. • 10% are heavy drinkers…who consume half of all the 241-269 alcohol produced 12th edition: • no other form of addiction or disability costs the US pp. 231-261 more than alcohol use/abuse annually Excessive alcohol use causes 88,000 deaths annually (chapter eight) twice as many as illicit drugs • lost work time, illness, insurance, accidents, medical costs take a toll on all of us…25% of all medical costs in the US are alcohol related Alcohol: The world’s most what is alcohol? dangerous drug? 13th, pp. 239-240; 12th pp. 232-233 The Lancet Medical Journal - 1 November, 2016 • alcohol is a byproduct of fermentation • In a recent article published in of vegetable or fruit pulp or ‘mash’ the British medical journal The this produces a concentration of Lancet, when considering the alcohol up to 14% drug’s damage to: • distillation is a further process by •one’s self capturing the vapors from heating • one’s family the mash, and mix this with water • the environment • proof is the measure of % of alcohol, which means the % • economic cost of alcohol is half of the ‘proof rating’ • Alcohol is the world’s most • some alcohol is 152 proof, or 71% alcohol most beers are damaging drug to individuals 8 proof, or 4% alcohol.
    [Show full text]
  • GCE a Level 1083/01 BUSINESS STUDIES –
    GCE A level 1083/01 S15-1083-01 BUSINESS STUDIES – BS3 A.M. WEDNESDAY, 10 June 2015 2 hours 1083 010001 ADDITIONAL MATERIALS In addition to this examination paper, you will need: • a calculator; • a 12 page answer book. INSTRUCTIONS TO CANDIDATES Use black ink or black ball-point pen. Answer all the questions. Write your answers in the separate answer book provided. INFORMATION FOR CANDIDATES The number of marks is given in brackets at the end of each question. You are reminded that assessment will take into account the quality of written communication used in answers that involve extended writing in questions 4 and 5. You are reminded that questions 4 and 5 are synoptic and so will test understanding of the connections between different elements of the subject. © WJEC CBAC Ltd. AM*(S15-1083-01) 2 Study the information provided about GlaxoSmithKline plc and answer the questions that follow. BACKGROUND GlaxoSmithKline plc (GSK) is a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. It has three primary areas of business: pharmaceuticals, vaccines and consumer healthcare. Its consumer products include 5 Ribena, Macleans toothpaste, Panadol headache pills, Lucozade and Horlicks. The company can trace its history back to 1715 when Sylvanus Bevan established his pharmacy in Plough Court in London. In 1880, his descendants founded Burroughs Wellcome and Company which, eventually in 1995, merged with the Australian company Glaxo to form Glaxo Wellcome. The American branch of the business can trace its history back to 1830 when John K Smith 10 opened his first drugstore.
    [Show full text]
  • Pharmaceutical Giant Consolidates Worldwide Facilities Management Services
    CASE STUDY From 300 to 3: Pharmaceutical Giant Consolidates Worldwide Facilities Management Services Client: GlaxoSmithKline The Opportunity Matter: Outsourcing contract strategy, UK-headquartered GlaxoSmithKline (GSK) is a FTSE structuring and negotiation 100-listed research-based pharmaceutical company that employs 99,000 people in more than 100 countries. GSK Area of Law: Outsourcing has a seven percent share of the world medicine/medical Result: Significantly increased profits and efficiency product market and, through its consumer health division, for GSK by replacing more than 300 sells products under household-name brands like alli, worldwide service providers using unique Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne contracts with a select number of global and Panadol. providers using standardised agreements. GSK has grown both organically and through acquisition, contracting service suppliers one at a time as the need arose. By the time it enlisted Pillsbury’s help, GSK’s facilities management services spanned 300 suppliers across multiple sites and product lines, each with its own locally developed service levels and pricing models. GSK sought to simplify its operating model with a stand- ardised, scalable solution with consistent, measurable service levels delivered through a few global providers. The Challenge The scale of the project added significant complexity to the lifecycle aspects of the arrangement—from strategy, due diligence, contracting and transition to operational management and global rollout. GSK selected
    [Show full text]
  • Bk Sans 005737.Pdf
    TABLE OF CONTENTS Procter & Gamble’s Earnings Per Share .3 Coca-Cola’s Earnings Per Share .3 Johnson & Johnson’s Earnings Per Share .4 United Continental’s Earnings Per Share .4 Ford Motor Company’s Earnings Per Share .5 Advance Micro Devices, Inc.’s Earnings Per Share .5 Compare Coca-Cola to Ford Motor Company .6 American Express Company .7 American Express Company Per Share Earnings History .8 The Bank of New York Mellon (BNY Mellon) .9 BNY Mellon EPS History / BNY Mellon BVPS History .10 Coca-Cola Company .11 ConocoPhillips .12 ConocoPhillips EPS History / ConocoPhillips BVPS History .13 Costco Wholesale Corporation .14 Costco EPS History / Costco BVPS History .15 GlaxoSmithKline .16 GSK’s brand-name products .17 GlaxoSmithKline’ Profile / GlaxoSmithKline’ History .18 Johnson & Johnson .19 Johnson & Johnson Per Share Book Value History .20 Kraft Foods, Inc .21 Kraft Foods EPS History / Kraft Foods BVPS History .22 Moody’s Corporation .23 Moody’s Corporation EPS History .24 Procter & Gamble Company .25 Procter & Gamble BVPS History .26 Sanofi S. A. .27 Sanofi A.S EPS ADR History / Sanofi A.S BVPS History .28 Torchmark Corporatio .29 Torchmark Corporation EPS History / Torchmark Corporation BVPS History .30 Union Pacific Corporation .31 Union Pacific Corporation NPM (Net Profit Margin) History .32 Union Pacific Corporation BVPS History / Union Pacific Corporation EPS History .32 U.S. Bancorp .33 U.S. Bankcorp EPS History / U.S. Bankcorp BVPS History .34 Wal-Mart Stores, Inc. .35 Walmart EPS History / Walmart BVPS History .36 Washington
    [Show full text]
  • Drunkorexia and Gender Role Conformity
    University of Northern Colorado Scholarship & Creative Works @ Digital UNC Dissertations Student Research 8-2020 Drunkorexia and Gender Role Conformity Sarah Zwetzig Follow this and additional works at: https://digscholarship.unco.edu/dissertations Recommended Citation Zwetzig, Sarah, "Drunkorexia and Gender Role Conformity" (2020). Dissertations. 694. https://digscholarship.unco.edu/dissertations/694 This Text is brought to you for free and open access by the Student Research at Scholarship & Creative Works @ Digital UNC. It has been accepted for inclusion in Dissertations by an authorized administrator of Scholarship & Creative Works @ Digital UNC. For more information, please contact [email protected]. © 2020 SARAH ZWETZIG ALL RIGHTS RESERVED UNIVERSITY OF NORTHERN COLORADO Greeley, Colorado The Graduate School DRUNKOREXIA AND GENDER ROLE CONFORMITY A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Sarah Zwetzig College of Education and Behavioral Sciences Department of Applied Psychology and Counselor Education August 2020 This Dissertation by: Sarah Zwetzig Entitled: Drunkorexia and Gender Role Conformity. has been approved as meeting the requirements for the Degree of Doctor of Philosophy in College of Education and Behavioral Sciences in Department of Applied Psychology and Counselor Education. Accepted by the Doctoral Committee: ___________________________________________________ Basilia Softas-Nall, Ph.D., Research Advisor ___________________________________________________
    [Show full text]
  • Glaxosmithkline ITA – Wikipedia
    GlaxoSmithKline - Wikipedia https://it.wikipedia.org/wiki/GlaxoSmithKline GlaxoSmithKline Da Wikipedia, l'enciclopedia libera. GlaxoSmithKline plc (Borsa di Londra: GSK (https://it.finance.yahoo.com/q?s=GSK.L), NYSE: GSK GlaxoSmithKline plc (https://www.nyse.com/quote/XNYS:GSK)) è una società britannica operante nel settore farmaceutico, biologico, e sanitario. GlaxoSmithKline è una società di ricerca con un vasto Stato Regno Unito portafoglio di prodotti farmaceutici che comprendono Forma Società per azioni antinfettivi del sistema nervoso centrale (SNC), societaria respiratorio, gastrointestinale/metabolico, oncologico e vaccini. Inoltre ha molti prodotti per l'igiene del Borse Borsa di Londra: GSK consumatore tra cui prodotti per l'igiene orale, bevande valori (https://it.finance.yahoo.com nutrizionali e medicinali da banco. È presente in 37 /q?s=GSK.L) nazioni ed in Italia possiede una sede a San Polo di NYSE: GSK Torrile, vicino a Parma. A Verona la Glaxo nasce il 30 (https://www.nyse.com marzo 1932 con il nome di Società anonima italiana /quote/XNYS:GSK) Nathan Bompiani, antesignana dell'odierna GlaxoSmithKline; dall'anno 2010 il centro ricerche di ISIN GB0009252882 Verona è condiviso con Aptuit[1]. L'Italia è stato il primo (http://www.isin.org/isin- insediamento estero dell'azienda che presto prenderà il preview nome Glaxo, dal greco "Galaktos", a simboleggiare uno /?isin=GB0009252882) dei suoi primi prodotti: il latte in polvere. Fondazione 2000 dalla fusione tra Glaxo Wellcome e SmithKline Beecham Indice Sede Londra principale
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 2015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals, Vaccines and Consumer Healthcare businesses Overview of 2015 Strategic report “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business. This progress means the Group is well positioned to return to core earnings growth in 2016.” Sir Andrew Witty, Chief Executive Officer Governance & remunerationPerformance Financial statements summary Investor information £23.9bn £10.3bn £5.7bn £3.9bn Group turnover Total operating profit Core operating profit Cash dividends paid (up 6% CER/up 1% CER (up >100% CER) a (down 9% CER/down 3% in 2015 pro-forma) a CER pro-forma)a £2.0bn 174.3p 75.7p 10 0 % New product sales b Total earnings per share Core earnings per share Markets now operating (up >100%) (up >100%, primarily (down 15% CER, primarily new commercial model reflecting impact of reflecting short-term dilution transaction gains) of the Novartis transaction)a ~40 20 ~13 % 1st Potential new medicines Potential to file up to Estimated internal In Access to Medicine and vaccines profiled at R&D 20 assets with regulators rate of return in R&D Index event, 80% of which have by 2020 in 2015 potential to be first-in-classc Footnotes a We use a number of adjusted measures to report the performance of our business, as described on page 54. These include core results, CER growth rates and pro-forma CER growth rates. A reconciliation of total results to core results is set out on page 62.
    [Show full text]
  • Biennial Review 2020
    Drug Free Schools and Campuses Regulations [EDGAR 86] Biennial Review Academic Years 2019 & 2020 The report has been compiled by: Emily Sears, MS, LCADC Zachary Hitchens, MS, LCADC, NCC Jaclyn Webber, MA December 2020 Table of Contents Executive Summary 3 Introduction to Towson University 4 Program Inventory and Assessment 5-15 Policy and Enforcement 16-18 AOD related highlights and significant accomplishments 19-20 Program strengths and areas of growth 21-25 Annual distribution protocol 26 Conclusion and recommendations 27 Appendices 28-75 2 Executive Summary This Biennial Report was compiled and written by the ATOD team, covering academic years 2018-2019 and 2019-2020. Contributions were made by campus partners to provide important information, updates, and data to support this review; contributions were made by the Office of Student Conduct & Civility Education, Human Resources, Fraternity & Sorority Life, and Housing and Residence Life to name a few. Assessment, survey, and evaluation data are important tools to help us better understand our campus community perceptions, behaviors, and needs which also serves to inform our programming goals. Consequently, this information gleaned from the CORE Survey, NCHA, and Maryland College Alcohol Survey, Party 101 evaluations, etc. also contributed largely to this report. 3 Introduction to Towson University Towson University is a public university located in Towson, Maryland, a suburb of Baltimore City. Rich in academia, the Baltimore metropolitan area boasts more than 20 colleges and universities with Towson University recognized as the largest in the immediate Baltimore area, and second-largest within the University System of Maryland. As noted on the Towson University website https://www.towson.edu/about/ataglance/, the Fall 2020 semester the total enrollment of Towson University was 21,917 students; composed of 18,730 undergraduate and 3,187 graduate students.
    [Show full text]
  • View a Hangover As Positive (Mallett, Marzell, Varvil-Weild, Turrisi, & Guttman, 2011)
    ABSTRACT COMPARING DRUNKOREXIA ACROSS ATHLETES AND NON-ATHLETES by Marina E. Galante Drunkorexia is known as the use of disordered eating strategies in response to or in preparation for future alcohol use (Rahal, Bryant, Darkes, Menzel, & Thompson, 2012). The aim of the current study is to assess the relationship between drunkorexia, athlete status, and sport type. Participants were 295 college students (82 male and 213 female) from a mid-sized Midwestern university. Students participated in an online survey that included items assessing alcohol consumption, the Rutgers Alcohol Problem Index (RAPI), the Eating Attitudes Test-26 (EAT- 26), and the Compensatory Eating and Behaviors in Response to Alcohol Consumption Scale (CEBRACS). Student-athletes had significantly lower EAT-26 and CEBRACS scores than non- athletes; RAPI scores did not significantly differ between the two groups. Certain sport athletes differed concerning CEBRACS diet/exercise subscales, EAT diet, and EAT total scores. Aesthetic athletes may be more susceptible to the combination of alcohol consumption and disordered eating practices than other sport athletes. COMPARING DRUNKOREXIA ACROSS ATHLETES AND NON-ATHLETES A Thesis Submitted to the Faculty of Miami University in partial fulfillments of the requirements for the degree of Master of Science Department of Kinesiology and Health by Marina Elizabeth Galante Miami University Oxford, OH 2015 Advisor _____________________ Rose Marie Ward, Ph.D. Reader ______________________ Robert Weinberg, Ph.D. Reader ______________________
    [Show full text]